KRAS and neoplasm: Consistently, pharmacological treatment with BAY-293, a selective inhibitor of SOS1:KRAS interaction47, resulted also in decreased cell proliferation of different KRASG12D-LUAD murine tumor cell lines such as KPB6, LKR10, and LKR13, exhibiting a closely similar antiproliferative effect than the specific KRASG12D inhibitor MRTX1133 (Fig. 7d).